Clinical trials: Insulin Resistance Syndrome X
Metabolic Syndrome X
Effects the Glycemic Index on Metabolic Risk Markers
Recent population studies have shown that the glycemic index (GI) of food products is positively associated with the risk of developing type 2 diabetes and cardiovascular disease (CVD).
- Trial name
- NCT00695825
- Testing
- Low GI+high GI, High GI+low GI
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Obesity, Metabolic Syndrome
The Monocyte Subsets in Obese Patients With and Without Metabolic Syndrome
Obesity is associated with a chronic low-grade inflammation characterized by macrophage infiltration in adipose tissue that induces insulin resistance and the appearance of metabolic syndrome (MS).
- Trial name
- NCT03241394
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ioannina
Metabolic Syndrome, Metabolic Syndrome Obesity
Impact of Medical Nutrition Therapy and Follow-Up Frequency on Metabolic Syndrome Parameters
There is no study that has investigated the effects of medical nutrition therapy and more frequent follow-up via telehealth on metabolic syndrome parameters in patients with MetS who have multiple metabolic disorders such as…
- Conditions
- Metabolic Syndrome, Metabolic Syndrome Obesity, Metabolic Syndrome Parameters
- Trial name
- NCT06813131
- Testing
- Dietary counseling, calling via telephone
- Where
- Turkey (Türkiye)
- Volunteers
- 93 people
- Sponsor
- Hacettepe University
Metabolic Syndrome x
The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study
Patients with metabolic syndrome, insulin resistance, and elevated triglycerides of 150 mg/dl or higher will be randomized to one of four groups: 1) placebo; 2) metformin; 3) fenofibrate; or 4) combined metformin and fenofibrate…
- Trial name
- NCT00400231
- Testing
- Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Insulin Resistance Syndrome
Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause
Background: In postmenopausal females, Insulin resistance is commonly encountered in clinical setting. Hyperbaric oxygen therapy have been proposed effective in lowering blood glucose level and improving function.
- Trial name
- NCT06806345
- Testing
- Hyperbaric oxygen therapy, Hypoglycemic Drug
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Metabolic Syndrome X
A Study on the Intervention of Metabolic Syndrome Patients With Exercise Prescription Based on Ventilatory Threshold Using Cardiopulmonary Exercise Test
Analyze the clinical intervention effects and differences of progressive precision exercise prescriptions formulated by two methods for determining exercise intensity on metabolic syndrome (MS).
- Trial name
- NCT06379204
- Testing
- the maximum physiological value standardized group, the ventilatory threshold individualized group
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Taiyuan Central Hospital of Shanxi Medical University
Cardiovascular Diseases, Metabolic Syndrome X
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients at risk of a first heart attack.
- Conditions
- Cardiovascular Diseases, Metabolic Syndrome X, Atherosclerosis
- Trial name
- PAD (NCT00272311)
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Florida Atlantic University
Hypertension, Metabolic Syndrome X
Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities
The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome.
- Trial name
- NCT00242814
- Testing
- Micardis, Amlodipine, Abdominal biopsy
- Where
- 31 sites in France
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Metabolic X Syndrome Dyslipidemia
MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)
This is a clinical trial in patients with Metabolic Syndrome and Dyslipidemia to study the effects of MK0767 on triglycerides.
- Trial name
- NCT00703690
- Testing
- MK0767, Comparator: fenofibrate
- Volunteers
- 436 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2, Metabolic Syndrome X
Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness
Cilostazol is an antiplatelet agent used to reduce the symptoms of intermittent claudication. Cilostazol inhibits phosphodiesterase III (PDE III), which causes it to be a vasodilator and inhibitor of platelet aggregation.
- Trial name
- NCT00573950
- Testing
- cilostazol
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Korea University Anam Hospital
Metabolic Syndrome X, Diabetes Mellitus, Type 2
Evaluation of Effect of Exercise on Prescription
The purpose of this study is to evaluate the effect of a primary healthcare intervention called 'Exercise on Prescription' aimed at increasing level of physical activity in a population of sedentary patients with increased risk…
- Conditions
- Metabolic Syndrome X, Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Trial name
- NCT00399997
- Testing
- Exercise on Prescription
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Southern Denmark
Metabolic Syndrome X, Overweight
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455325)
- Testing
- Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Washington University School of Medicine
Metabolic Syndrome X
Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study
Ezetimibe has been shown to inhibit cholesterol absorption and several lines of evidence from in vitro systems and animal models suggest that this effect is associated with an increase in low-density lipoprotein (LDL) receptor…
- Trial name
- EZEmRNA (NCT01849068)
- Testing
- Ezetimibe
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Laval University
Diabetes, Nutrition Disorders
OPTIFIT-Optimal Fiber Trial for Diabetes Prevention
High intake of insoluble fiber is strongly associated with a reduced incidence of diabetes and cardiovascular events in prospective observation studies.
- Conditions
- Diabetes, Nutrition Disorders, Obesity, Overweight
- Trial name
- NCT01681173
- Testing
- Fiber
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- German Institute of Human Nutrition
Iron Overload, Metabolic Syndrome X
Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging
Iron excess is increasingly regarded as an important cofactor in the morbidity attributed to many disorders. Assessment of body iron stores by measurement of serum ferritin concentrations has poor specificity and the most…
- Conditions
- Iron Overload, Metabolic Syndrome X, Hepatitis B, Hepatitis C
- Trial name
- SURFER (NCT00401336)
- Testing
- Magnetic resonance imaging multiecho gradient-echo sequence
- Where
- 10 sites in France, Spain
- Volunteers
- 250 people
- Sponsor
- Rennes University Hospital
Cardiovascular Diseases, Heart Diseases
Central Obesity and Disease Risk in Japanese Americans
To conduct a longitudinal study of central obesity and related risk factors found to be associated with hypertension and atherosclerotic cardiovascular disease (ASCVD) in a previously-examined cross-sectional cohort of…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Hypertension
- Trial name
- NCT00005365
- Sponsor
- University of Washington
Metabolic Syndrome X
Weight Loss in Diabetic, Older Obese Adults
This study examines the effects of weight loss and aerobic exercise training on sugar metabolism and other risk factors for heart disease in obese older individuals.
- Trial name
- NCT00108329
- Testing
- Weight Loss
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Adverse Effect, Atherosclerosis, Coronary
Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease
Pioglitazone, a medication of thiazolidinedione group, is capable of triggering the peroxisome proliferator-activated receptors (PPAR-γ).
- Conditions
- Adverse Effect, Atherosclerosis, Coronary, Insulin Resistance Syndrome
- Trial name
- EFFORT (NCT03011775)
- Testing
- Pioglitazone 15 mg Tablet, Isosorbide Dinitrate 10Mg Tablet, Acetylsalicylic Acid 75Mg Tablet
- Where
- Ukraine
- Volunteers
- 43 people
- Sponsor
- Ukrainian Medical Stomatological Academy
Metabolic Syndrome X, Overweight
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455403)
- Testing
- Chloroquine
- Where
- United States
- Volunteers
- 357 people
- Sponsor
- Washington University School of Medicine
Insulin Resistance - Type A, Insulin Resistance - Type B
A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance
A multicenter, open-label, single-arm study with regard to the efficacy and safety of empagliflozin in patients with refractory diabetes mellitus with insulin resistance
- Conditions
- Insulin Resistance - Type A, Insulin Resistance - Type B, Lipoatrophic Diabetes Mellitus, Insulin Resistance Syndrome
- Trial name
- EMPIRE-01 (NCT04018365)
- Testing
- Empagliflozin Tablets
- Where
- 5 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kobe University